SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
0.213
0.00 (-0.19%)
At close: Dec 20, 2024, 4:00 PM
0.219
+0.006 (2.67%)
After-hours: Dec 20, 2024, 7:28 PM EST
SciSparc Employees
SciSparc had 3 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$582,333
Profits / Employee
-$1,894,667
Market Cap
764.92K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Scorpius Holdings | 84 |
| China SXT Pharmaceuticals | 75 |
| Molecular Templates | 62 |
| TC Biopharm (Holdings) | 41 |
| Revelation Biosciences | 9 |
| Aclarion | 6 |
SPRC News
- 5 days ago - SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company - GlobeNewsWire
- 2 months ago - SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - GlobeNewsWire
- 3 months ago - SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewsWire
- 3 months ago - SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 3 months ago - SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment - GlobeNewsWire
- 3 months ago - SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - GlobeNewsWire
- 3 months ago - SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer - GlobeNewsWire
- 3 months ago - SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - GlobeNewsWire